None listed
Conditions
Interventions
Others(Disital Therapeutics) : This study consists of an 8-week intervention program, with each group receiving the following interventions:
? Experimental Group (BlueKare-T Intervention Group)
Parti
Sponsors
HippoT&C
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1)Individuals aged 19 years or older 2) Individuals who meet the diagnostic criteria for Major Depressive Disorder according to the DSM-5, or who have been diagnosed with a Depressive Episode (F32) according to the ICD-10 at the time of screening 3)Individuals with a BDI score of 14 or higher 4)Individuals who have no difficulty reading and writing in Korean 5)Individuals who have no difficulty using mobile applications on general-purpose devices (e.g., smartphones or tablet PCs) 6)Individuals who have received a sufficient explanation about the clinical trial, fully understand the information, voluntarily agree to participate, and provide written consent to comply with the study instructions
Exclusion criteria
Exclusion criteria: 1)Individuals with serious psychiatric disorders other than depressive disorder, such as bipolar disorder, schizophrenia, or substance use disorders, or with clinically significant neurological disorders and brain injuries (e.g., stroke, cerebral hemorrhage, multiple sclerosis, epilepsy), or with clinically significant physical illnesses (e.g., liver failure, malignant diseases, metabolic disorders, infectious diseases) 2)Individuals who have attempted suicide within one month prior to screening, or who are deemed to be at high risk of suicide by a psychiatrist 3)Individuals who are undergoing psychotherapy for depression (e.g., cognitive behavioral therapy, interpersonal therapy, psychoanalytic psychotherapy, or psychoanalysis) within three months prior to screening 4)Individuals who have had changes in dosage of allowed concomitant medications for depression—such as antidepressants, mood stabilizers, or antipsychotics—within one month prior to screening ? This exclusion does not apply if the type and dosage of medications remain unchanged during the month prior to screening (including continued prescriptions). Dosage adjustments are allowed within one month prior to screening for the following medications: propranolol, benztropine, trihexyphenidyl HCl, benzodiazepines (e.g., diazepam, clonazepam, bromazepam, lorazepam, alprazolam, triazolam), benzodiazepine-like drugs (e.g., etizolam), zolpidem, and zolpiclone. 5)Individuals deemed by the investigator to be otherwise unsuitable for participation in the clinical trial for any reason
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Beck Depression Inventory | — |
Secondary
| Measure | Time frame |
|---|---|
| Patient Health Questionnaire-9 ;Montgomery-Åsberg Depression Rating Scale;Beck Anxiety Inventory;Short Form 36-Item Health Survey;Korean Version of the Perceived Stress Scale;Rosenberg Self-Esteem Scale | — |
Countries
Korea, Republic of
Contacts
Public ContactHongjin Jeon
Sungkyunkwan University
Outcome results
None listed